Yasminelle((R)): a new low-dose combined oral contraceptive containing drospirenone.
Yasminelle((R)) is a newly developed combined oral contraceptive that contains ethinyl estradiol 20 microg and drospirenone 3 mg. Yasminelle is unlike other low-dose ethinyl estradiol combined oral contraceptives, since drospirenone produces antiandrogenic and antimineralocorticoid effects that offer various benefits including a reduced potential for estrogen-induced water retention. Pharmacological and pharmacokinetic data have been derived from clinical experience with ethinyl estradiol 30 microg and drospirenone 3 mg (Yasmin((R))). Clinical studies with Yasminelle have shown a high degree of contraceptive efficacy, similar to that of combined oral contraceptives that contain a low dose of ethinyl estradiol combined with other progestins. These studies have also demonstrated that Yasminelle produces excellent cycle control and has a good tolerability profile, similar to that of other low-dose ethinyl estradiol combined oral contraceptives.
Sillem
Martin
M
Department of Obstetrics & Gynaecology, DRK Krankenhaus, Marktstr. 104, D-56564 Neuwied, Germany. martin.sillem@drk-kh-neuwied.de.